Black Diamond Therapeutics, Inc. (BDTX)

Market Cap	286.52M
Revenue (ttm)	n/a
Net Income (ttm)	-82.44M
Shares Out	51.72M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,143
Open	5.16
Previous Close	5.11
Day's Range	5.16 - 5.63
52-Week Range	1.43 - 6.85
Beta	2.64
Analysts	Strong Buy
Price Target	12.25 (+117.58%)
Earnings Date	May 7, 2024

About BDTX

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF Mas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2020
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: BDTX

Analyst Forecast

According to 4 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price forecast is $12.25, which is an increase of 117.58% from the latest price.

Price Target

$12.25

(117.58% upside)

Analyst Consensus: Strong Buy